NDC 43353-0747-92: Furosemide 20 mg Tablet, Bottle of 270
This is a package of 270 tablets of Furosemide 20 mg Tablet from Aphena Pharma Solutions - Tennessee, LLC, first listed with the FDA Nov 1983 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 43353-747-92 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 43353 labeler · 747 product · 92 package
- Package marketed since
- Aug 22, 2017
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 270 EA per package
- Barcode (UPC-A, from the NDC)
- 3 4335374792 6
- FDA record last changed
- Jul 24, 2026
Other active recalls for Furosemide (different manufacturers) — 2 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 008208
- GCN: 34961
- GPI-14 (Medi-Span): 37200030000305
- HICL (First Databank): 003660
- AHFS class code: 24:36.08.00
- RxCUI (RxNorm): 310429
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Loop Diuretic class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Furosemide is used alone or with other medications to treat high blood pressure. Furosemide is used to treat edema excess fluid held in body tissues caused by various medical problems. Furosemide is in a class of medications called diuretics ('water pills'). It works by causing the kidneys to get rid of unneeded water and salt from the body. High blood pressure is a common condition. When not treated, it can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. This damage may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vi...
Read the full MedlinePlus article ↗- It's a water pill that clears extra fluid caused by heart failure, liver cirrhosis or kidney disease. The oral forms can also treat high blood pressure. Injection forms are used wh...
- Tablets and oral solution are taken by mouth, usually once or twice daily. Your prescriber finds the lowest dose that works and may suggest only certain days of the week. Always fo...
- Dizziness, headache, nausea, diarrhea and muscle cramps can happen. Call your doctor right away for ringing in your ears or hearing loss, severe dizziness or fainting, trouble urin...
- What side effects should I expect, and when should I call?
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Furosemide — tap one for details:
Furosemide may be associated with lower levels of 9 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.1154 | $31.16 / 270 tablets |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 43353-0747-30 43353-747-30 Main listing | 30 TABLET in 1 BOTTLE, PLASTIC | 2017-05-01 | — | Active |
| 43353-0747-45 43353-747-45 | 45 TABLET in 1 BOTTLE, PLASTIC | 2017-08-22 | — | Active |
| 43353-0747-53 43353-747-53 | 60 TABLET in 1 BOTTLE, PLASTIC | 2017-05-01 | — | Active |
| 43353-0747-60 43353-747-60 | 90 TABLET in 1 BOTTLE, PLASTIC | 2011-08-02 | — | Active |
| 43353-0747-80 43353-747-80 | 180 TABLET in 1 BOTTLE, PLASTIC | 2017-05-01 | — | Active |
| 43353-0747-92 You're viewing this | 270 TABLET in 1 BOTTLE, PLASTIC | 2017-08-22 | — | Active |
You're viewing the largest of 6 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 43353-0747-30?
What NDC number is used to bill for this package of Furosemide 20 mg Tablet?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Furosemide 20 mg 00054-4297-25 | Hikma | 100 tablets | $0.025 | AB | Availability likely | — |
| Furosemide 20 mg 00054-8297-25 | Hikma | 100 tablets | $0.025 | AB | Availability likely | — |
| Furosemide 20 mg 00904-7177-61 | Major | 100 tablets | $0.025 | AB | Availability likely | — |
| Furosemide 20 mg 43547-0401-10 | Solco | 100 tablets | $0.025 | AB | Availability likely | — |
| Furosemide 20 mg 62135-0753-90 | Chartwell | 90 tablets | $0.025 | — | Availability likely | — |
| Furosemide 20 mg 64980-0562-01 | Rising | 100 tablets | $0.025 | AB | Availability likely | — |
| Furosemide 20 mg 69315-0116-01 | Leading | 100 tablets | $0.025 | AB | Availability likely | — |
| Furosemide 20 mg 83980-0002-01 | Ipca | 100 tablets | $0.025 | AB | Availability likely | — |
| Lasix 20 mg 30698-0067-01 | Validus | 100 tablets | $0.749 | — | Availability likely | — |
| Furosemide 20 mg 00615-8368-05 | NCS | 15 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 10135-0832-01 | Marlex | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 17224-0178-21 | Calvin | 21 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 42291-0468-01 | AvKARE | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 43063-0702-21 | PD-Rx | 21 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 43063-0849-21 | PD-Rx | 21 tablets | — | AB | FDA listed | — |
| Furosemide 20 mgthis 43353-0747-92 | Aphena | 270 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 50090-5429-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 50090-6219-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 50090-6642-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 50090-6942-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 50090-7706-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 50090-7708-00 | A-S | 90 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 51655-0269-25 | Northwind | 60 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 51655-0310-53 | Northwind | 10 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 51655-0481-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 55154-2349-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 59651-0796-91 | Aurobindo | 100000 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 61919-0242-30 | DIRECT | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 63187-0517-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 63187-0739-10 | Proficient | 10 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 63561-0164-01 | Granulation | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 63629-1214-01 | Bryant | 1000 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 63629-1215-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 67046-0768-03 | Coupler | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 67046-1589-03 | Coupler | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 67296-2136-01 | Redpharm | 3 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 68071-1708-01 | NuCare | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 68071-3673-03 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 68071-4534-01 | NuCare | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 68788-6948-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 68788-8870-01 | Prefferred | 100 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 70518-0050-00 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 70518-2528-01 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 70518-3061-00 | REMEDYREPACK | 5 tablets | — | AB | Discontinued | — |
| Furosemide 20 mg 70518-3757-00 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 70518-4679-00 | REMEDYREPACK | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 71335-0384-01 | Bryant | 30 tablets | — | AB | Discontinued | — |
| Furosemide 20 mg 71335-0852-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 71335-2319-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 71610-0096-30 | Aphena | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 71610-0635-30 | Aphena | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 71610-0843-30 | Aphena | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 72162-1360-00 | Bryant | 1000 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 72789-0030-30 | PD-Rx | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 82868-0050-30 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Furosemide 20 mg 87441-0033-01 | Unit | 30 tablets | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Furosemide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII 368GB5141J
A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.
-
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
-
UNII 4ELV7Z65AP
Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Aphena Pharma Solutions - Tennessee, LLC labeler code 43353
- Paroxetine 40 mg Tablet, Film Coated NDC 43353-544-15
- Paroxetine 20 mg Tablet, Film Coated NDC 43353-554-15
- Diphenoxylate Hydrochloride and Atropine Sulfate 2.5 mg; .025 mg Tablet NDC 43353-594-30
- Paroxetine 20 mg Tablet, Film Coated NDC 43353-713-15
- Hydrochlorothiazide 50 mg Tablet NDC 43353-717-09
- Hydrochlorothiazide 25 mg Tablet NDC 43353-719-15
- Diazepam 2 mg Tablet NDC 43353-825-30
- Omeprazole 40 mg Capsule, Delayed Release NDC 43353-829-60
- Atenolol 50 mg Tablet NDC 43353-834-30
- Metolazone 2.5 mg Tablet NDC 43353-890-09
- Terbinafine Hydrochloride 250 mg Tablet NDC 43353-893-16
- Chantix varenicline tartrate 1 mg Tablet, Film Coated NDC 43353-899-05
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.
Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Edema Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Adults The usual initial dose of furosemide is 20 to 80 mg given as a single dose. Ordinarily a prompt diuresis ensues.
If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (e.g., at 8 am and 2 pm).
The dose of furosemide may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states. Edema may be most efficiently and safely mobilized by giving furosemide on 2 to 4 consecutive days each week. When doses exceeding 80 mg/day are given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable (See PRECAUTIONS : Laboratory Tests ).
Geriatric Patients In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range (See PRECAUTIONS : Geriatric Use ). Pediatric Patients The usual initial dose of oral furosemide in pediatric patients is 2 mg/kg body weight, given as a single dose. If the diuretic response is not satisfactory after the initial dose, dosage may be increased by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose.
Doses greater than 6 mg/kg body weight are not recommended. For maintenance therapy in pediatric patients, the dose should be adjusted to the minimum effective level. Hypertension Therapy should be individualized according to the patient’s response to gain maximal therapeutic response and to determine the minimal dose needed to maintain the therapeutic response.
Adults The usual initial dose of furosemide for hypertension is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents.
Changes in blood pressure must be carefully monitored when furosemide is used with other antihypertensive drugs, especially during initial therapy. To prevent excessive drop in blood pressure, the dosage of other agents should be reduced by at least 50 percent when furosemide is added to the regimen. As the blood pressure falls under the potentiating effect of furosemide, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.
Geriatric Patients In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range (See PRECAUTIONS : Geriatric Use ).
⛔ Contraindications ▾
CONTRAINDICATIONS Furosemide is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.
⚠️ Warnings ▾
WARNINGS In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis.
Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported.
Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hyopproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) (See PRECAUTIONS: Drug Interactions ).
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions 1. hepatic encephalopathy in patients with hepatocellular insufficiency 2. pancreatitis 3. jaundice (intrahepatic cholestatic jaundice) 4. increased liver enzymes 5. anorexia 6. oral and gastric irritation 7. cramping 8. diarrhea 9. constipation 10. nausea 11. vomiting Systemic Hypersensitivity Reactions 1. severe anaphylactic or anaphylactoid reations (e.g. with shock) 2. systemic vasculitis 3. interstitial nephritis 4. necrotizing angiitis Central Nervous System Reactions 1. tinnitus and hearing loss 2. paresthesias 3. vertigo 4. dizziness 5. headache 6. blurred vision 7. xanthopsia Hematologic Reactions 1. aplastic anemia 2. thrombocytopenia 3. agranulocytosis 4. hemolytic anemia 5. leukopenia 6. anemia 7. eosinophilia Dermatologic-Hypersensitivity Reactions 1. toxic epidermal necrolysis 2.
Stevens-Johnson Syndrome 3. erythema multiforme 4. drug rash with eosinophilia and systemic symptoms 5. acute generalized exanthematous pustulosis 6. exfoliative dermatitis 7. bullous pemphigoid 8. purpura 9. photosensitivity 10. rash 11. pruritus 12. urticaria Cardiovascular Reaction 1. Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics. 2.
Increase in cholesterol and triglyceride serum levels. Other Reactions 1. hyperglycemia 2. glycosuria 3. hyperuricemia 4. muscle spasm 5. weakness 6. restlessness 7. urinary bladder spasm 8. thrombophlebitis 9. fever Whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn.
🆘 Overdosage ▾
OVERDOSAGE The principal signs and symptoms of overdose with furosemide are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action. The acute toxicity of furosemide has been determined in mice, rats and dogs. In all three, the oral LD 50 exceeded 1000 mg/kg body weight, while the intravenous LD 50 ranged from 300 to 680 mg/kg.
The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats. The concentration of furosemide in biological fluids associated with toxicity or death is not known. Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses.
Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy). Hemodialysis does not accelerate furosemide elimination.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the absorption of sodium and chloride not only in the proximal and distal tubules but also in the loop of Henle. The high degree of efficacy is largely due to the unique site of action.
The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone. Recent evidence suggests that furosemide glucuronide is the only or at least the major biotransformation product of furosemide in man. Furosemide is extensively bound to plasma proteins, mainly to albumin.
Plasma concentrations ranging from 1 to 400 mcg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations. The onset of diuresis following oral administration is within 1 hour.
The peak effect occurs within the first or second hour. The duration of diuretic effect is 6 to 8 hours. In fasted normal men, the mean bioavailability of furosemide from Furosemide Tablets and Furosemide Oral Solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
Although furosemide is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. Peak plasma concentrations increase with increasing dose but times-to-peak do not differ among doses. The terminal half-life of furosemide is approximately 2 hours.
Significantly more furosemide is excreted in urine following the IV injection than after the tablet or oral solution. There are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine. Geriatric Population Furosemide binding to albumin may be reduced in elderly patients.
Furosemide is predominantly excreted unchanged in the urine. The renal clearance of furosemide after intravenous administration in older healthy male subjects (60 to 70 years of age) is statistically significantly smaller than in younger healthy male subjects (20 to 35 years of age). The initial diuretic effect of furosemide in older subjects is decreased relative to younger subjects (See PRECAUTIONS : Geriatric Use ).
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Furosemide Tablets USP 20 mg tablets are supplied as white, flat tablets with beveled edges, product identification “54 840” debossed on one side. NDC 0054-8297-25: Unit dose amber blisters, 10 Tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper NDC 0054-4297-25: Bottle of 100 Tablets NDC 0054-4297-31: Bottle of 1000 Tablets 40 mg tablets are supplied as white, flat tablets with beveled edges, scored on one side and product identification “54 583” debossed on one side. NDC 0054-8299-25: Unit dose amber blisters, 10 Tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper NDC 0054-4299-25: Bottle of 100 Tablets NDC 0054-4299-31: Bottle of 1000 Tablets 80 mg tablets are supplied as white, flat tablets with beveled edges, scored on one side and product identification “54 533” debossed on one side.
NDC 0054-8301-25: Unit dose amber blisters, 10 Tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper NDC 0054-4301-25: Bottle of 100 Tablets NDC 0054-4301-29: Bottle of 500 Tablets Store and Dispense Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Note: Dispense in a tight, light-resistant, child-resistant container as defined in the USP/NF. Exposure to light may cause slight discoloration. Discolored tablets should not be dispensed.
Protect From Moisture. PROTECT FROM LIGHT. Furosemide Oral Solution USP 10 mg per mL oral solution is supplied as a (orange-flavored) clear, orange-colored solution.
NDC 0054-3294-46: Bottle of 60 mL Dispense only in this bottle and only with the calibrated dropper provided. NDC 0054-3294-50: Bottle of 120 mL Dispense only in this bottle. PROTECT FROM LIGHT.
NOTE: DISCARD OPENED BOTTLE AFTER 90 DAYS. 40 mg per 5 mL oral solution is supplied as a (pineapple-peach flavored) clear, orange-colored solution. NDC 0054-3298-63: Bottle of 500 mL Dispense in a tight, light-resistant, child-resistant container as defined in the USP/NF.
PROTECT FROM LIGHT. Store and Dispense Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724 4052002//11 Revised January 2016
📋 Description ▾
DESCRIPTION Each tablet for oral administration contains: Furosemide USP . . . . . . . . . . . . . . . . 20 mg, 40 mg and 80 mg Each mL of Oral Solution for oral administration contains: Furosemide USP . . . . . . . . . . . . . . . . 10 mg per mL or 8 mg (40 mg per 5 mL) Furosemide is a diuretic which is an anthranilic acid derivative.
Chemically, it is 4-chloro- N -furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to slightly yellow, crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids.
The CAS Registry Number is 54-31-9. The structural formula is as follows: C 12 H 11 ClN 2 O 5 S M.W. 330.74 Furosemide Tablets USP are available for oral administration containing 20 mg, 40 mg or 80 mg of Furosemide USP.
The tablets meet Dissolution Test 1. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, sodium starch glycolate and stearic acid. Furosemide Oral Solution USP is also available for oral administration containing either 10 mg per mL or 40 mg per 5 mL.
The oral solution contains the following inactive ingredients: D and C Yellow No. 10, FD and C Yellow No. 6, flavors, potassium carbonate 1½ hydrate, propylene glycol, sorbitol solution and water.
The 10 mg/mL solution is orange flavored and contains prosweet liquid and also saccharin sodium. The 40 mg/5 mL solution is pineapple-peach flavored and contains sweet tone. chem.jpg
⚠️ Precautions ▾
PRECAUTIONS General Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients. As with any effective diuretic, electrolyte depletion may occur during furosemide therapy, especially in patients receiving higher doses and a restricted salt intake. Hypokalemia may develop with furosemide, especially with brisk diuresis, inadequate oral electrolyte intake, when cirrhosis is present or during concomitant use of corticosteroids, ACTH, licorice in large amounts, or prolonged use of laxatives.
Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially myocardial effects. All patients receiving furosemide therapy should be observed for these signs or symptoms of fluid or electrolyte imbalance (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia or hypocalcemia): dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.
Increases in blood glucose and alterations in glucose tolerance tests (with abnormalities of the fasting and 2-hour postprandial sugar) have been observed, and rarely, precipitation of diabetes mellitus has been reported. In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. Thus, these patients require careful monitoring, especially during the initial stages of treatment.
In patients at high risk for radiocontrast nephropathy furosemide can lead to a higher incidence of deterioration in renal function after receiving radiocontrast compared to high-risk patients who received only intravenous hydration prior to receiving radiocontrast. In patients with hypoproteinemia (e.g., associated with nephrotic syndrome) the effect of furosemide may be weakened and its ototoxicity potentiated. Asymptomatic hyperuricemia can occur and gout may rarely be precipitated.
Patients allergic to sulfonamides may also be allergic to furosemide. The possibility exists of exacerbation or activation of systemic lupus erythematosus. As with many other drugs, patients should be observed regularly for the possible occurrence of blood dyscrasias, liver or kidney damage, or other idiosyncratic reactions.
Information for Patients Patients receiving furosemide should be advised that they may experience symptoms from excessive fluid and/or electrolyte losses. The postural hypotension that sometimes occurs can usually be managed by getting up slowly. Potassium supplements and/or dietary measures may be needed to control or avoid hypokalemia.
Patients with diabetes mellitus should be told that furosemide may increase blood glucose levels and thereby affect urine glucose tests. The skin of some patients may be more sensitive to the effects of sunlight while taking furosemide. Hypertensive patients should avoid medications that may increase blood pressure, including over-the-counter products for appetite suppression and cold symptoms.
Laboratory Tests Serum electrolytes (particularly potassium), CO 2 , creatinine and BUN should be determined frequently during the first few months of furosemide therapy and periodically thereafter. Serum and urine electrolyte determinations are particularly important when the patient is vomiting profusely or receiving parenteral fluids. Abnormalities should be corrected or the drug temporarily withdrawn.
Other medications may also influence serum electrolytes. Reversible elevations of BUN may occur and are associated with dehydration, which should be avoided, particularly in patients with renal insufficiency. Urine and blood glucose should be checked periodically in diabetics receiving furosemide, even in those s… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL Furosemide 20mg - 30 Tablets
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL Furosemide 40mg - 30 Tablets
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |